Tokio Marine Asset Management Co. Ltd. Has $379,000 Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,603 shares of the medical research company’s stock after buying an additional 133 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Charles River Laboratories International were worth $379,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in CRL. Meritage Group LP acquired a new stake in shares of Charles River Laboratories International during the third quarter worth approximately $173,174,000. Rhenman & Partners Asset Management AB acquired a new stake in shares of Charles River Laboratories International during the third quarter worth approximately $48,603,000. Montrusco Bolton Investments Inc. boosted its holdings in shares of Charles River Laboratories International by 35.8% during the third quarter. Montrusco Bolton Investments Inc. now owns 855,387 shares of the medical research company’s stock worth $164,058,000 after purchasing an additional 225,562 shares during the period. Armistice Capital LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter worth approximately $30,573,000. Finally, abrdn plc lifted its stake in Charles River Laboratories International by 872.0% in the fourth quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock valued at $28,795,000 after acquiring an additional 109,275 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRL has been the subject of a number of analyst reports. Argus lifted their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, March 18th. TheStreet upgraded shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Evercore ISI lifted their target price on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research note on Thursday, February 15th. Guggenheim cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Finally, Citigroup lifted their target price on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $253.23.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $229.03 on Monday. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00. The stock has a market cap of $11.80 billion, a P/E ratio of 24.87, a PEG ratio of 1.79 and a beta of 1.40. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. The company has a fifty day moving average price of $253.48 and a 200 day moving average price of $223.01.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $991.25 million. During the same quarter in the prior year, the company posted $2.98 EPS. The business’s revenue was down 7.9% on a year-over-year basis. Analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Insider Activity

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, VP William D. Barbo sold 4,050 shares of the stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares in the company, valued at approximately $5,685,431.50. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).